SCHEMBL6501524

SCHEMBL6501524

Cc1ccc(C2=C(C(=O)Nc3ccc(N4CCNCC4)nc3)CCCC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.53
RAB9A P51151 2/20 0.53
CYP1A2 P05177 2/20 0.52
MAPT P10636 2/20 0.52
CYP2C19 P33261 1/20 0.52
IKBKE Q14164 1/20 0.45
TBK1 Q9UHD2 1/20 0.45
KCNH2 Q12809 1/20 0.45
CACNA1C Q13936 1/20 0.45
ASIC3 Q9UHC3 1/20 0.45
MAPK7 Q13164 1/20 0.44
DYRK1A Q13627 4/20 0.43
CLK2 P49760 3/20 0.43
CLK3 P49761 2/20 0.43
GSK3B P49841 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC2 Q92769 1/20 0.42
KCNQ3 O43525 1/20 0.42
KCNQ2 O43526 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491337 0.87 MAPT (0.55) MAPTIKBKETBK1MAPK7HDAC3
SCHEMBL6502056 0.87 L3MBTL1 (0.54) L3MBTL1RAB9ACYP1A2MAPTCYP2C19
SCHEMBL6499989 0.84 NPC1 (0.53) L3MBTL1RAB9AMAPTCYP2C19IRAK4
SCHEMBL6492114 0.80 L3MBTL1 (0.47) L3MBTL1RAB9ACYP1A2MAPTCYP2C19
SCHEMBL6489230 0.78 PRKAA2 (0.47) L3MBTL1RAB9ACYP1A2MAPTCYP2C19
SCHEMBL13553093 0.77 RAB9A (0.65) L3MBTL1RAB9ACYP1A2MAPTCYP2C19
SCHEMBL6531877 0.73 SMN1; SMN2 (0.54) MAPTKDM4EDDB1CRBN
SCHEMBL7490372 0.72 MAPT (0.59) L3MBTL1RAB9ACYP1A2MAPTCYP2C19
SCHEMBL25416941 0.72 RAB9A (0.47) L3MBTL1RAB9ACYP1A2MAPTCYP2C19
SCHEMBL30426798 0.72 RAB9A (0.47) L3MBTL1RAB9ACYP1A2MAPTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 L3MBTL1 2276/4885RAB9A 4382/4885CYP1A2 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.